



27 Birchwood  
Avenue  
London  
N10 3BE

T +44 (0) 208 365 2185  
m +44 (0) 7818012891  
info@phmrconsulting.com  
www.phmrconsulting.com

**Directors**

Mark Ratcliffe  
BSc MSc PhD  
Peter Hudson  
BSc MSc

# Lung Cancer

Economic/ health outcome publication alerts added in

## January 2008

Searches found 50 articles that met criteria: 4 are commercially significant of which 2 are business and scientific critical and are reviewed.

Papers reviewed this month:

Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. *J Clin Oncol.* 2008 Jan 20;26(3):468-73.

Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. *J Clin Oncol.* 2008 Jan 1;26(1):60-5.

**phmr consulting ltd.**  
Registered in England  
Number 6551482  
Registered office  
Melville House  
8-12 Woodhouse  
Road  
London N12 0RG